Twist Bioscience Capital Expenditures (CapEx) Growth & History (TWST)
Twist Bioscience's capital expenditures (capex) was $28.0M for fiscal 2025.
View full Twist Bioscience company overviewTwist Bioscience annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $28.0M | $22.9M | +451.69% |
| 2024 | 2024-09-30 | $5.1M | −$22.7M | −81.73% |
| 2023 | 2023-09-30 | $27.8M | −$74.1M | −72.73% |
| 2022 | 2022-09-30 | $101.9M | $74.8M | +276.40% |
| 2021 | 2021-09-30 | $27.1M | $17.2M | +174.23% |
| 2020 | 2020-09-30 | $9.9M | −$4.9M | −33.13% |
| 2019 | 2019-09-30 | $14.8M | $11.1M | +300.14% |
| 2018 | 2018-09-30 | $3.7M | −$2.9M | −44.07% |
| 2017 | 2017-09-30 | $6.6M | — | — |
Twist Bioscience quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $9.8M | $598,000 | +6.52% |
| Q2 2026 | 2026-03-31 | $7.9M | $3.7M | +90.32% |
| Q1 2026 | 2025-12-31 | $10.0M | $7.7M | +339.77% |
| Q4 2025 | 2025-09-30 | $12.4M | $10.4M | +520.73% |
| Q3 2025 | 2025-06-30 | $9.2M | $8.2M | +849.74% |
| Q2 2025 | 2025-03-31 | $4.1M | $3.5M | +587.23% |
| Q1 2025 | 2024-12-31 | $2.3M | $762,000 | +50.60% |
| Q4 2024 | 2024-09-30 | $2.0M | −$391,000 | −16.34% |
| Q3 2024 | 2024-06-30 | $965,000 | −$3.5M | −78.60% |
| Q2 2024 | 2024-03-31 | $603,000 | −$8.4M | −93.34% |
| Q1 2024 | 2023-12-31 | $1.5M | −$10.3M | −87.26% |
| Q4 2023 | 2023-09-30 | $2.4M | −$14.1M | −85.46% |
| Q3 2023 | 2023-06-30 | $4.5M | −$36.1M | −88.91% |
| Q2 2023 | 2023-03-31 | $9.1M | −$22.9M | −71.68% |
| Q1 2023 | 2022-12-31 | $11.8M | −$959,000 | −7.50% |
| Q4 2022 | 2022-09-30 | $16.5M | $8.4M | +103.51% |
| Q3 2022 | 2022-06-30 | $40.6M | $33.7M | +485.45% |
| Q2 2022 | 2022-03-31 | $32.0M | $23.6M | +280.55% |
| Q1 2022 | 2021-12-31 | $12.8M | $9.2M | +252.25% |
| Q4 2021 | 2021-09-30 | $8.1M | $5.9M | +263.55% |
| Q3 2021 | 2021-06-30 | $6.9M | $4.1M | +143.75% |
| Q2 2021 | 2021-03-31 | $8.4M | $5.7M | +206.94% |
| Q1 2021 | 2020-12-31 | $3.6M | $1.6M | +76.34% |
| Q4 2020 | 2020-09-30 | $2.2M | −$1.7M | −42.85% |
| Q3 2020 | 2020-06-30 | $2.8M | −$2.3M | −44.93% |
| Q2 2020 | 2020-03-31 | $2.7M | −$1.0M | −27.40% |
| Q1 2020 | 2019-12-31 | $2.1M | $136,000 | +7.08% |
| Q4 2019 | 2019-09-30 | $3.9M | $2.8M | +271.82% |
| Q3 2019 | 2019-06-30 | $5.2M | $4.5M | +722.26% |
| Q2 2019 | 2019-03-31 | $3.8M | $3.3M | +652.50% |
| Q1 2019 | 2018-12-31 | $1.9M | $411,000 | +27.20% |
| Q4 2018 | 2018-09-30 | $1.0M | — | — |
| Q3 2018 | 2018-06-30 | $629,000 | — | — |
| Q2 2018 | 2018-03-31 | $501,000 | — | — |
| Q1 2018 | 2017-12-31 | $1.5M | — | — |
Twist Bioscience capital expenditures (capex) trends
Over the last five fiscal years, Twist Bioscience's capital expenditures (capex) increased from $9.9M to $28.0M, a change of $18.1M. The latest reported quarter, Q3 2026, shows $9.8M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Twist Bioscience source filings ↗